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Conjugative transfer of plasmid DNA via close cell–cell junctions is
the main route by which antibiotic resistance genes spread be-
tween bacterial strains. Relaxases are essential for conjugative
transfer and act by cleaving DNA strands and forming covalent
phosphotyrosine linkages. Based on data indicating that multity-
rosine relaxase enzymes can accommodate two phosphotyrosine
intermediates within their divalent metal-containing active sites,
we hypothesized that bisphosphonates would inhibit relaxase
activity and conjugative DNA transfer. We identified bisphospho-
nates that are nanomolar inhibitors of the F plasmid conjugative
relaxase in vitro. Furthermore, we used cell-based assays to dem-
onstrate that these compounds are highly effective at preventing
DNA transfer and at selectively killing cells harboring conjugative
plasmids. Two potent inhibitors, clodronate and etidronate, are
already clinically approved to treat bone loss. Thus, the inhibition
of conjugative relaxases is a potentially novel antimicrobial ap-
proach, one that selectively targets bacteria capable of transferring
antibiotic resistance and generating multidrug resistant strains.
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Conjugative elements are responsible for the majority ofhorizontal gene transfers within and between bacterial
strains (reviewed in ref. 1), as first described for the Escherichia
coli F plasmid by Lederberg and Tatum in 1946 (2). Conjugative
DNA transfer is also the central mechanism by which antibiotic
resistance and virulence factors are propagated in bacterial
populations (reviewed in ref. 3). Indeed, it is well established that
antibiotic resistance can be rapidly acquired in clinical settings
and that such acquisition is critically dependent on conjugative
DNA transfer (reviewed in ref. 4). Small-molecule inhibition of
conjugation could prove to be a powerful method for curbing the
generation and spread of multidrug-resistant strains. Past studies
suggested that various antibiotics, polycyclic chemicals, and
crude extracts inhibit conjugation at concentrations less than the
antibacterial minimum inhibitory concentration (5–11); how-
ever, most of these effects have been attributed to nonconjuga-
tion-specific inhibition of bacterial growth or DNA synthesis
(12–15). This study describes a bottom-up approach used to
identify the first small molecule inhibitors of conjugative DNA
transfer that target an enzyme of the conjugative system.
The DNA relaxase is a central enzyme in each conjugative
system (16–18) and thus is a prime target for inhibition. The
conjugative relaxase initiates DNA transfer with a site- and
strand-specific ssDNA nick in the transferred strand (T-strand)
at the origin of transfer (oriT), forming a covalent 5-
phosphotyrosine intermediate (16, 19–23). The nicked T-strand
moves from the donor cell (plasmid) to the recipient cell
(plasmid) via an intercellular junction mediated by a type IV
secretion system (reviewed in refs. 19, 24, and 25). The relaxase
completes DNA transfer by reversing the covalent phosphoty-
rosine linkage and releasing the T-strand. In the F plasmid, this
relaxase is located in the N-terminal domain of a large multi-
functional protein, TraI (DNA helicase I) (22, 23, 26–28). Some
conjugative relaxases use one active-site tyrosine [e.g., IncQ
RSF1010 MobA (29), IncP RP4 TraI (30, 31), IncI R64 NikA
(32), Agrobacterium Ti VirD2 (33), and Tn5252 MocA/BmgA
(34), where R indicates plasmids that propagate antibiotic
resistance]. F-like relaxases [e.g., IncF R1 and R100 plasmid
TraIs (28), IncN R46 and pCU1 TraIs (35), IncW R388 TrwC
(36), and Pseudomonas IncP9 pWW0 TraC (37)] maintain a
conserved, bifurcated constellation of two to five tyrosines near
their N termini. The most common arrangement is four tyrosines
(Y1–Y4; tyrosines 16, 17, 23, and 24 in F TraI) with pairs Y1/2
and Y3/4 separated by a variable linker region. Crystal structures
show that all four tyrosines are proximal to a bound metal ion
[this study and others (38–41)]. Optimal relaxase cleavage,
ligation, and transfer of ssDNA require the metal ion and two
catalytic tyrosines, one from each pair (42). F TraI relaxase
shares significant sequence identity with relaxases of many R
plasmids (e.g., 98% with R100 TraI); thus, the F plasmid serves
as a model system for examining conjugative plasmids and the
inhibition of conjugative transfer.
In this study we first sought to understand the role that the
relaxase enzyme plays in the initiation and termination of DNA
conjugation and then sought to use that information to identify
potent relaxase-specific inhibitors. Our results establish that the
conjugative DNA transfer process can be selectively disrupted by
relaxase-targeted compounds, including some clinically ap-
proved drugs. This is a potentially novel antimicrobial approach,
one that could be used to purge from microbial populations the
bacteria capable of propagating antibiotic resistance genes.
Results
We determined the 2.4-Å crystal structure of the 300-residue
N-terminal relaxase domain of F plasmid TraI (N300) with a
tyrosine-16 to phenylalanine mutation (Y1 of F TraI; Y16F)
[Fig. 1A and supporting information (SI) Table 1]. The structure
of N300 is similar to those of a 330-residue F TraI fragment (39,
41) (N330) and the relaxase domain of R388 TrwC (38, 40) (SI
Fig. 5). Crystallization required a 9-base ssDNA oligonucleotide
consisting of the F oriT nick site sequence. Despite the Y16F
mutation, which reduces N300 DNA cleavage 600-fold, we
observed electron density for just one DNA base in the active site
(Fig. 1 A; SI Fig. 6). We interpreted this as the oriT thymidine
immediately upstream of the scissile phosphate (1 Thy). We
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also observed density for a bound metal ion, chelated by three
conserved histidine side chains (soft ligands, i.e., uncharged and
high polarizability). Despite unusual soft chelation, we interpret
the bound metal as a divalent magnesium ion (a hard center, i.e.,
low polarizability and a preference for charged ligands) based on
bond lengths, electron density, and octahedral coordination. A
survey of magnesium-binding proteins in the Protein Data Bank
revealed that the chelation of Mg2 by neutral residues is
diagnostic of a site that simultaneously binds to multiple phos-
phate groups (SI Table 2). Mutation of the metal-chelating
residue histidine-159 to glutamic acid (thus reducing the effec-
tive charge of the metal site) eliminated relaxase activity (SI Fig.
7). These data indicate that the 2 charge on the bound metal
ion is critical to relaxase function.
We then considered models for conjugative DNA transfer that
would require the observed 2 metal ion and two catalytically
competent tyrosine residues (Fig. 1B). In the case of simple
transfer (Fig. 1B, green), a single catalytic tyrosine is sufficient
for successful intercellular DNA transfer. However, if the free
3-hydroxyl product of relaxase-mediated DNA cleavage be-
comes a substrate for concomitant plasmid replication (CPR;
Fig. 1B, purple), analogous to rolling circle replication (43), then
two tyrosines would be required to resolve the replicative oriT
intermediate and release the T-strand to complete transfer. CPR
events explain the reported low-frequency generation of greater
than unit-length conjugative plasmids (44). Although CPR may
not be the primary conjugative pathway, plasmids with relaxases
capable of resolving CPR intermediates would be expected to
have a selective advantage. Single-tyrosine relaxases could
achieve resolution of CPR intermediates through relaxase mul-
timerization (45) or cooperation with a second nonrelaxase
protein (46). The ability to resolve undesirable replication
products would also confer oriT specific recombinase activity
between plasmids (47, 48) or between tandem oriT repeats on
the same plasmid (46, 49). However, for our purposes, a key
prediction that arose from this model is that multityrosine
relaxases are capable of accommodating two phosphotyrosine
intermediates simultaneously within their active sites. The need
to handle dual phosphotyrosine intermediates would explain the
key features of the TraI relaxase outlined above: the presence of
two catalytically competent tyrosines and the requirement for a
metal ion with an obligate 2 charge.
Based on the prediction that multityrosine relaxases employ
two simultaneous phosphotyrosine intermediates coordinated to
one magnesium ion, we hypothesized that simple bisphospho-
nates would bind the magnesium center and thus inhibit F TraI
relaxase activity and conjugative transfer. To test this hypothesis,
a kinetic assay using fluorophore-labeled oriT ssDNA for cleav-
age by the F TraI relaxase domain (TraI N300) was developed
to complement existing radiolabel-based techniques (50, 51).
Imidobisphosphate (PNP), a simple and relatively stable
bisphosphonate, was the first compound examined in this assay
(Fig. 2A). We found that PNP is a nanomolar inhibitor of TraI
relaxase activity in vitro. Analysis of cleavage velocity curves
revealed that PNP is a mixed-type (specifically, noncompetitive)
inhibitor of TraI, with apparent competitive (Kic,app) and un-
competitive (Kiu,app) inhibition constants of 2.0–2.4 nM and
2.7–3.5 nM, respectively. Thus, a simple bisphosphonate serves
as a potent inhibitor of a multityrosine relaxase activity in vitro.
To determine whether PNP derives its inhibitory power by
binding to the TraI relaxase active site, TraI N300 Y16F crystals
were soaked with PNP and the x-ray structure was determined
to 3.0-Å resolution (N300PNP) (SI Table 1). As in the N300
structure, three of the six magnesium octahedral coordination
positions are filled by histidine side chains, the fourth is filled by
the 3-hydroxyl of the scissile thymidine, and the fifth is occluded
by the Y16F side chain (Fig. 2B). Unlike the N300 structure, a
5 simulated-annealing omit electron density peak appears in
the sixth coordination position (SI Fig. 8), indicating the binding
of a single PNP phosphate group within 3.7 Å of the magnesium
ion. The second PNP phosphate was not observed, because of
either disorder or, more likely, hydrolysis by a water molecule
activated by the adjacent 2 metal (52–55). The N300PNP
Fig. 1. F TraI N300 Y16F bound to the scissile thymidine and a two-path model
of F-like bacterial conjugation. (A) N300 Y16F active site with a metal ion (blue
sphere) chelated by three histidines and the 1 Thy 3-hydroxyl. Y16F occludes a
fifth octahedral coordination site. (B) Cleavage by the first tyrosine forms a
covalent phosphotyrosine intermediate (red circle) on the T (red) strand. Transfer
with CPR diverges from simple transfer when the 3-hydroxyl left by initial
cleavagebecomesasubstratefor replication(bluestrand).ThenewlycreatedoriT
requires a second cleavage event and second phosphotyrosine (purple circle).








structure supports the conclusion that PNP inhibits TraI by
binding to the relaxase catalytic site.
The N300PNP structure revealed a novel phosphate binding
site, which allowed us to generate a potential model for the
second phosphotyrosine intermediate in the relaxase active site.
By rotating the first -helix (A; lower right corner of Fig. 1 A)
to match the orientation observed in the R388 TraI homologue,
TrwC (40), and extending helicity through tyrosine-24 (Y4 of F
TraI), tyrosine-23 (Y3 of F TraI) reorients such that its side chain
hydroxyl overlaps with the N300PNP phosphate position (Fig.
2C). In this orientation tyrosine-24 also makes an aromatic
stacking interaction with the side chain of tryptophan 278
(W278), a residue that is conserved in relaxases that have Y3/4
pairs. This model explains how two phosphotyrosines, one at
Y16 and one at Y23, can be accommodated within the active site
and in the process fulfill the octahedral coordination geometry
of a bound magnesium ion.
A variety of compounds were then examined for their ability
to inhibit the F TraI relaxase in vitro. A coarse screen (200 nM
concentrations and pH 7.4) of 11 bisphosphonates and three
negative controls (sodium chloride, dibasic potassium phos-
phate, and ampicillin, none of which exhibited relaxase inhibi-
tion) yielded five additional inhibitors: methylenediphosphonic
acid (PCP), iminobis(methylphosphonic acid) (PCNCP),
etidronic acid (ETIDRO), clodronic acid (CLODRO), and
1,2-bis(dimethoxyphosphoryl)benzene (PBENP) (Fig. 3). Re-
sults from this screen reveal that effective inhibitors have two
phosphonate moieties separated by three or fewer atoms and
have no additional negative charge at pH 7.4. Four clinically
approved bisphosphonates were tested; these drugs are used to
treat bone loss by inhibiting farnesyl diphosphate synthase
(reviewed in ref. 56). The simplest, ETIDRO and CLODRO,
inhibited the TraI relaxase, whereas pamidronic acid and
neridronic acid, which have an alkyl-amine side chain, did not.
Two other inhibitors identified, PCP and PNP, have been used
as radioisotope carriers in humans (57, 58). Pyrophosphate was
not examined because of its rapid hydrolysis in aqueous solution.
The simplest inhibitors, PCP, ETIDRO, and CLODRO, were
then characterized further by using a kinetic assay and exhibited
purely competitive inhibition, with Kic,app values ranging from 3
to 145 nM (SI Fig. 9). Taken together with the PNP results, these
data validate the prediction that F-like conjugative relaxases can
accommodate two phosphotyrosine intermediates simulta-
neously within their active sites. Significantly, these data also
establish that bisphosphonates (including clinically approved
compounds) potently inhibit the in vitro relaxase activity of F
TraI with Ki values in the nanomolar range.
We next asked whether PNP could impact conjugative DNA
transfer between living bacterial cells. F E. coli were mated with
F E. coli in dilute media and in the presence of increasing
concentrations of PNP. The resulting mixture was applied to agar
plates with antibiotic selection for transconjugants (newly
formed F cells). Colony counts revealed that PNP inhibited
Fig. 2. Relaxase inhibition by PNP. (A) N300 oriT ssDNA cleavage velocity (v0)
inhibited by PNP (error bars represent compounded standard errors from time
course parameter estimates; n  3). Competitive/uncompetitive inhibition
constants (Kic/Kiu) and uninhibited Michaelis constant/maximum velocity (Km/
Vmax) are from nonlinear regression and Cornish-Bowden/Eisenthal direct
linear plot analyses. Velocities for 100 and 10,000 nM PNP, estimated from low
signal, were excluded from calculations. (B) N300 Y16F active sites with PNP
(red) and without (orange). Only one PNP moiety was observed (purple). Y16F
occludes the sixth coordination site. Residues 236–263 and 266 were disor-
dered (small orange spheres). (C) Dual phosphotyrosine intermediate confor-
mation model (red) constructed from the N300PNP structure. Helix A was
rotated 120° about the helical axis to match that of TrwC structure 1OMH,
and helicity was extended through A and kinked about histidine-146.
Important side chains (red sticks), PNP (purple sticks), a hypothetical second
phosphate (purple circle), the bound metal (blue sphere), and the scissile
thymidine (from 1OMH; blue) are shown over the TraI active-site cleft molec-
ular surface.
Fig. 3. Bisphosphonates examined for relaxase inhibition. Chemicals exam-
ined for inhibition of TraI activity and F conjugation and for toxicity versus E.
coli strains. Boxed chemicals were potent in vitro TraI inhibitors. In cell testing
showed that PNP and PBENP were most effective at decreasing F population,
CLODRO and ETIDRO were most effective at decreasing transconjugant pop-
ulation, and PCP and PCNCP were effective at both.
12284  www.pnas.orgcgidoi10.1073pnas.0702760104 Lujan et al.
DNA transfer with an EC50 of 10 M, the lowest concentration
tested in this assay (Fig. 4A). We also found that PNP selectively
kills F donor cells with an EC50 of 10 M (compared with low
millimolar EC50 against F recipient cells). This suggests that the
TraI relaxase sensitizes F cells to a toxic effect of PNP. Minimal
cell growth was observed in control mating mixtures, so de-
creases in donor cell count relative to controls are attributed
primarily to cell death rather than to a lack of cell growth. Thus,
inhibitor-dependant decreases represent bactericidal rather than
bacteriastatic effects. Strains containing only the TraI gene
(F/TraI), an F plasmid lacking the TraI gene (F/TraI), or
an F plasmid with the four relaxase active-site tyrosines mutated
to phenylalanine (F/TraI 4Y-F) behaved like F cells in this
assay, in that they were resistant to the lethal effects of PNP. The
impact on DNA donor cell survival depends on the presence of
an F plasmid and a catalytically active relaxase. Thus, the simple
bisphosphonate PNP enters living bacteria, inhibits conjugative
DNA transfer, and selectively kills cells in an active relaxase-
dependent manner. As hypothesized, small bisphosphonates
appear most effective against dual tyrosine relaxases. Studies
Fig. 4. Effects of F TraI inhibitors on E. coli survival and conjugation. Color coding for lines, bars, and symbols: orange, F; red, F/TraI; cyan, F/TraI; green,
F/TraI 4Y-F (inactive relaxase); blue, F/TraI; yellow, transconjugants (DNA transfer). (A) Colony counts after PNP incubation (normalized versus uninhibited
controls; averaged). Error bars represent standard errors (n  5). (B) EC50 values from relative cell counts. Colored bars indicate averaged curve EC50 values. Error
bars represent  1 SD envelope EC50 values (SI Fig. 10). Potent in vitro inhibitors are located above a strong black line, with negative controls below. Selectivities
are EC50 ratios for given inhibitors and strains. (C) Relative cell counts with median EC50 values (drop arrows; colored by strain). Error bars represent the standard
error (n  3).








with the single tyrosine relaxase-encoding R27 plasmid reveal
plasmid-dependent cell lethality only above 1 mM PNP (data not
shown).
A fluorescence-based 96-well assay was then used to examine
further these effects and to screen additional compounds for the
ability to impact cell survival and DNA transfer in living bacterial
cells. This higher-throughput cell enumeration assay used an
oxygen-quenched fluorophore imbedded within a hydrophobic
gel; the concentration of live (oxygen-consuming) cells is pro-
portional to fluorescence (59). The six compounds effective at
inhibiting TraI relaxase activity in vitro (PNP, PCP, PCNCP,
PBENP, CLODRO, and ETIDRO) (Fig. 3), along with two
controls (pamidronic acid and K2HPO4) were examined for their
impacts on F and F cell survival and on DNA transfer (Fig.
4 B and C). Pamidronic acid and K2HPO4, which had no effect
on TraI relaxase activity in vitro, showed little effect on cell
survival and DNA transfer in these cell-based assays, exhibiting
EC50 values greater than the highest concentrations tested (10
mM and 100 mM, respectively) and no selectivity for F over F
cells. In contrast, all six potent in vitro TraI relaxase inhibitors
were also effective in living E. coli cells. EC50 values for inhibiting
F donor cell survival ranged from 10 M (ETIDRO) to 16 nM
(PCNCP), and for inhibiting conjugative DNA transfer from 31
M (PNP) to 110 nM (CLODRO). These compounds have little
effect on F recipient cells, with EC50 values ranging from 0.34
mM (ETIDRO) to 100 mM (PBENP), which represents 30- to
106-fold selectivity for F cells, respectively. In general, PNP and
PBENP were more effective at inhibiting F cell survival,
ETIDRO and CLODRO were more effective at inhibiting DNA
transfer, and PCP and PCNCP were effective against both F
cell survival and DNA transfer (Figs. 3 and 4 B and C). The
ranges for EC50 values (Fig. 4B) were derived considering the
standard error of the survival curves (Fig. 4C). Thus, for the most
extreme case of ETIDRO, the median EC50 for transfer inhibi-
tion is 330 nM with a range of 1.1 M to 10 pM (SI Fig. 10).
Taken together, however, these data establish that relaxases can
be inhibited with nanomolar affinity within living bacterial cells
and that this inhibition both limits DNA transfer and selectively
kills microbes harboring conjugative plasmids.
Discussion
This study outlines a potentially novel antimicrobial paradigm
that specifically targets the DNA relaxase enzyme required to
initiate and terminate the process of bacterial conjugation. The
compounds identified could be used alone or in combination
with existing antibiotics to treat recalcitrant bacterial infections.
Other antibiotics and natural extracts have been reported to
disrupt conjugative DNA transfer and the presence of plasmids
within actively dividing bacterial cells (5–15). In each case,
however, the macromolecular target of those compounds was
not understood and their mechanism of action has not been
determined. We took a bottom-up approach to targeted DNA
conjugation by considering first the mechanism and role of a
single enzyme (the DNA relaxase) in this process and then
identifying inhibitors to test a specific mechanistic hypothesis
(that two phosphotyrosine intermediates can be accommodated
in the relaxase active site). Although our data were collected on
the relaxase from the well established F plasmid that was first
identified in 1946 (2), the F conjugative machinery shares up to
99% sequence identify with R plasmids containing dual tyrosine
relaxases that transfer antibiotic resistance in the wild. Thus, our
approach may be effective against plasmids involved in propa-
gating a range of resistance genes and virulence factors, many of
which play an important role in clinical infections (60–62).
In addition to inhibiting DNA transfer, we show that simple
bisphosphonates selectively purge populations of bacteria con-
taining a conjugative plasmid with an active relaxase enzyme.
However, because TraI is F plasmid-encoded, not an essential E.
coli enzyme, and was not expected to play a significant role in
isolated F cells, this relaxase-dependent cell lethality was a
surprise. Several mechanisms could be envisioned to explain this
observation, and future studies will be required to distinguish
between them. One possibility is that relaxases engage in cycles
of plasmid DNA cleavage and religation that are uncoupled from
mating and conjugative DNA transfer and that the disruption of
that process results in a competitive disadvantage relative to cells
without conjugative plasmids. Indeed, inspection of Fig. 4C
reveals that a direct competition appears to exist between
plasmid propagation and donor cell survival (note particularly
PNP, PCNCP, PBENP, and CLODRO). F donor cell survival
is enhanced at higher bisphosphonate concentrations to the
detriment of plasmid propagation via conjugative transfer. These
observations suggest a classic ‘‘zero-sum game’’ in which toxic
relaxase-specific bisphosphonate inhibitors pit the interests of
endosymbiont plasmids against those of their bacterial hosts.
We show that the clinically approved bisphosphonates etidr-
onate (Didronel) and clodronate (Bonefos), but not other
bisphosphonate therapeutics, are potently effective at killing F
cells and preventing conjugative DNA transfer. These particular
compounds could also be combined with existing antibiotics to
create potent antimicrobial cocktails. Etidronate and clodronate
exhibit low absorption (63, 64) and can be administered at high
oral doses (SI Table 3). Extrapolating from our results, approved
doses of etidronate and clodronate would be expected kill 90%
of plasmid cells and to stop 80% of conjugative transfer
within the gastrointestinal tract. Such results are relatively mild,
given the large bacterial populations present in the gastrointes-
tinal tract or at wound sites, but may be enough shift the balance
toward success in a variety of recalcitrant clinical infections,
especially given the prevalence of conjugative plasmids within
multidrug-resistant bacterial strains. The treatment of skin in-
fections, primary sites of nosocomial antibiotic resistance trans-
fer, using the topical applications of bisphosphonates may also be
effective. In summary, this study establishes conjugative relax-
ases as a unique antimicrobial target. Our results suggest that
approved therapeutics could have an immediate impact, alone or
in combination with existing antibiotics, in the prevention of
resistance propagation during clinical treatment of bacterial
infections and in extending the lifetime of our antibiotic arsenal.
Methods
Protein Expression, Purification, and Crystallization. F plasmid TraI
residues 1–300 bearing a phenylalanine substitution for ty-
rosine-16 (N300 Y16F) were subcloned into the pTYB2 vector
(NEB, Ipswich, MA) and overexpressed in E. coli at 30°C. The
fusion with intein-chitin-binding-domain (CBD) was purified on
chitin resin (NEB) and the CBD tag cleaved with DTT. N300
Y16F crystals were grown at room temperature by the hanging-
drop vapor diffusion method in the presence of ssDNA (5-
GGTGTGGTG-3). The crystals were cryoprotected and frozen
in liquid nitrogen for data collection at 77 K. PNP was added to
the cryoprotectant for the N300PNP structure.
Data Collection, Structure Determination, and Refinement. X-ray
diffraction data were collected at the Argonne National Labo-
ratory Advanced Photon Source on the SER-CAT and GM-CAT
beamlines. Diffraction data were indexed and scaled with
HKL2000 and MOSFLM (CCP4) (65). Initial phases were
determined by molecular replacement in Molrep (CCP4) (65)
with apo-TraI [Protein Data Bank ID code 1P4D (41)] as a
search model (SI Table 1). The Protein Data Bank ID codes for
the structures without and with PNP are 2Q7T and 2Q7U,
respectively. Structural figures were constructed in PyMol (66).
OriT Cleavage Assays. Gel-based cleavage assays were performed
as previously described (50). Fluorescent cleavage reactions were
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performed with biotinylated oriT ssDNA, either fluorescein
end-labeled or postreaction hybridized to an end-labeled probe.
Twelve to 96 parallel reactions were run on 96-well plates (37°C),
stopped with SDS and EDTA (80°C), and read on streptavidin-
coated 96- or 384-well plates.
Conjugative Mating Assays. Liquid mating assays were performed
as previously described (26) except that HMS174 cells replaced
HMS174 (DE3) cells. Where applicable, inhibitor candidates
were added at reaction initiation and removed before strain
selection/detection. Strains were selected, and cell concentra-
tions were quantified either on agar plates or in antibiotic-laden
media on Oxygen Biosensor 96-well round-bottom plates (BD
Biosciences) (59). In toxicity assays on agar plates, donor and
recipients cells remained separate. In mating assays, donor and
recipient cells were mixed at a 1:9 ratio. All inhibitor exposures
were 100 min.
Additional Details. Detailed descriptions of all methods and data
analyses are included in SI Methods.
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